How Will Lilly’s Collaboration with a Top Saudi Hospital Revolutionise Early Alzheimer’s Detection?
- Healthcare and General Service
- March 12, 2025
Highlights
- KFSHRC and Eli Lilly Saudi Arabia have signed a MoU to establish a regional Neuroscience Centre for Alzheimer’s disease
- It aims to improve healthcare professionals’ education and training
King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) have signed a Memorandum of Understanding (MoU) to establish KFSHRC’s Neuroscience Centre as a regional centre of excellence in Alzheimer’s Disease.
The partnership aims to collaborate on educating and training healthcare professionals in Saudi Arabia on neurodegenerative diseases like Alzheimer’s, drawing from global research insights and best practices. Lilly will transfer manufacturing expertise to KFSHRC, enabling future production of Positron Emission Tomography (PET) imaging agents and tracers in Saudi Arabia.
The collaboration leverages localised PET imaging technology for earlier diagnosis and better patient outcomes. The knowledge and technology transfer equips Saudi specialists with the latest advancements, enabling them to deliver world-class care. This alliance brings global innovations directly to patients and their families, underscoring KFSHRC’s commitment to their well-being and bringing new hope closer to home.
